Back to mobile site

Baird Reiterates Outperform Rating on Ocular Therapeutix (OCUL)

December 3, 2024 6:32 AM EST Send to a Friend
Baird analyst Colleen Kusy reiterated an Outperform rating and $17.00 price target on Ocular Therapeutix (NASDAQ: OCUL).The analyst commented: "Significant ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login